Novo Nordisk B A/S (NOVO-B.CO) Financials
NOVO-B.CO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 314.5 billion | 207.9 billion |
| 2023-09-30 | 300.1 billion | 207.1 billion |
| 2023-06-30 | 280.8 billion | 190.3 billion |
| 2023-03-31 | 250.0 billion | 170.2 billion |
NOVO-B.CO Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | -6.9 billion | ? |
| 2023-09-30 | 30.3 billion | ? |
| 2023-06-30 | 21.5 billion | -4.5 billion |
| 2023-03-31 | 25.0 billion | ? |
NOVO-B.CO Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | 22.0 billion |
| 2023-09-30 | 22.5 billion |
| 2023-06-30 | 19.4 billion |
| 2023-03-31 | 19.8 billion |
NOVO-B.CO Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | - | - | 5.7 billion |
| 2023-09-30 | - | - | - |
| 2023-06-30 | 36.4 billion | - | - |
| 2023-03-31 | 27.8 billion | - | - |
NOVO-B.CO Shares Outstanding
NOVO-B.CO Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 16.4 billion | 10.5 billion | 18.6 billion | - |
| 2023-09-30 | 10.6 billion | 8.1 billion | 14.1 billion | - |
| 2023-06-30 | 7.0 billion | 7.1 billion | 1.1 billion | 14.3 billion |
| 2023-03-31 | 4.8 billion | 6.7 billion | 1.1 billion | 12.4 billion |
NOVO-B.CO Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 65.9 billion | 10.0 billion |
| 2023-09-30 | 58.7 billion | 9.7 billion |
| 2023-06-30 | 54.3 billion | 7.9 billion |
| 2023-03-31 | 53.4 billion | 8.2 billion |
NOVO-B.CO
Price: DKK897.70
Dividend Yield: 0.01%
Forward Dividend Yield: 1.42%
Payout Ratio: 76.74%
Dividend Per Share: 12.80 DKK
Earnings Per Share: 18.24 DKK
P/E Ratio: 46.85
Exchange: CPH
Sector: Healthcare
Industry: Biotechnology
Volume: 2.2 million
Market Capitalization: 3.9 trillion
Average Dividend Frequency: 1
Years Paying Dividends: 25
DGR3: 30.00%
DGR5: 14.62%
DGR10: 28.69%
DGR20: 27.43%